The popularity of Sildenafil initially sparked a boom for pharma, nevertheless recent shifts present a complicated scenario for investors. Off-patent alternatives are eroding profits, and ongoing litigation add further complexity to the situation. While specific companies might still benefit from related services, the general trend suggests a cauti